-
-
-
-
-
-
-
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
-
-
-
-
-
-
-
Lilly (LLY) Receives FDA Priority Review for the Selpercatinib NDA
-
-
-
-
-
-
-
U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
12,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All